Search | Clinical Trials Finder

Conditions: Bipolar Mania, Bipolar Disorder
Interventions: Placebo, Ziprasidone Oral Capsule; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 584 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 73
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 59 more

Conditions: ADHD
Interventions: NRCT-101-SR, Placebo; Drug
Lead sponsor: Neurocentria, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 223 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 9
States / cities: Garden Grove, California • Lakeland, Florida • Maitland, Florida + 6 more

Conditions: Atrophic Vaginitis
Interventions: Generic Estradiol Vaginal Cream USP, 0.01%, Estrace® Vaginal Cream USP, 0.01%, Vehicle Vaginal Cream; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 30 Years to 75 Years · Female only
Enrollment: 663 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 44
States / cities: Tucson, Arizona • La Mesa, California • Sacramento, California + 33 more

Conditions: Chikungunya Virus
Interventions: CHIKV VLP vaccine, Placebo; Biological
Lead sponsor: Bavarian Nordic; Industry
Eligibility: 1 Year to 11 Years
Enrollment: 720 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 8
States / cities: Fountain Valley, California • Washington D.C., District of Columbia • Miami, Florida + 4 more

Conditions: Healthy
Interventions: BMS-986166, Placebo matching BMS-986166; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Community-Acquired Bacterial Pneumonia (CABP)
Interventions: JNJ-32729463, moxifloxacin, JNJ-32729463 (Open-Label); Drug
Lead sponsor: Furiex Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 13
States / cities: Mobile, Alabama • Sylmar, California • Orlando, Florida + 8 more

Conditions: Dementia Moderate, Dementia, Mild, Alzheimer Disease
Interventions: Xanamem, Placebo; Drug
Lead sponsor: Actinogen Medical; Industry
Eligibility: 50 Years and older
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 19
States / cities: Carlsbad, California • Sherman Oaks, California • Denver, Colorado + 16 more

Conditions: 2019 Novel Coronavirus Infection, COVID-19 Virus Infection, SARS Coronavirus 2 Infection, SARS-CoV-2 Infection, Respiratory Distress Syndrome, Adult, Adult Respiratory Distress Syndrome
Interventions: USB002, Placebo; Drug
Lead sponsor: US Biotest, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Acute Otitis Media
Interventions: amoxicillin-clavulanate, Placebo; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 6 Months to 23 Months
Enrollment: 291 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Migraine
Interventions: ASY202, Placebo; Combination Product
Lead sponsor: Aspeya, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 6
States / cities: Walnut Creek, California • Orlando, Florida • Las Vegas, Nevada + 2 more

Conditions: COVID-19
Interventions: ALG-097558, Dabigatran, Itraconazole, Placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Neuropathy;Peripheral, Chemotherapy-induced Peripheral Neuropathy
Interventions: BXQ-350, Placebo; Drug · Other
Lead sponsor: Bexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 3
States / cities: Cincinnati, Ohio • Columbus, Ohio • Nashville, Tennessee

Conditions: Vitiligo
Interventions: Rapamycin, Placebo; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 13 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Influenza, Human
Interventions: FLU-Q-PAN H7N9 Formulation 1, FLU-Q-PAN H7N9 Formulation 2, FLU-Q-PAN H7N9 Formulation 3, AS03B, AS03A, Placebo; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 833 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 8
States / cities: Stockbridge, Georgia • Meridian, Idaho • Cary, North Carolina + 5 more

Conditions: Herpes Zoster
Interventions: Herpes zoster vaccine GSK1437173A, Placebo; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 50 Years and older
Enrollment: 410 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 7
States / cities: Phoenix, Arizona • Pembroke Pines, Florida • Las Vegas, Nevada + 4 more

Conditions: Schizophrenia and Related Disorders, Mitochondrial Alteration, Cognitive Impairment
Interventions: MitoQ, Placebo; Drug
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years to 35 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: New Haven, Connecticut • Belmont, Massachusetts

Conditions: Peanut Allergy, Peanut Hypersensitivity, Peanut-Induced Anaphylaxis, Immune System Diseases
Interventions: PVX-108, Placebo; Biological
Lead sponsor: Aravax Pty Ltd; Industry
Eligibility: 4 Years to 17 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 8
States / cities: Little Rock, Arkansas • Rolling Hills Estates, California • Atlanta, Georgia + 5 more

Conditions: Infection, Human Immunodeficiency Virus, HIV Infections
Interventions: GSK2838232 100 mg tablet, GSK2838232 50 mg capsule, Ritonavir 100 mg tablets, Placebo for GSK2838232 tablets; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Migraine
Interventions: Galcanezumab, Placebo; Drug · Other
Lead sponsor: Diamond Headache Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: SSM, Mastocytosis, Indolent, Mastocytosis, Systemic, Mastocytosis, ISM, BMM, Smoldering Systemic Mastocytosis, Bone Marrow Mastocytosis
Interventions: Bezuclastinib Tablets (Formulation A), Bezuclastinib Tablets (Formulation B), Placebo Tablets; Drug
Lead sponsor: Cogent Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 237 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 24
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 20 more

Conditions: Angelman Syndrome
Interventions: Levodopa, Placebo Oral Capsule; Drug
Lead sponsor: Wen-Hann Tan; Other
Eligibility: 4 Years to 12 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 7
States / cities: San Diego, California • San Francisco, California • Boston, Massachusetts + 4 more

Conditions: Respiratory Syncytial Virus Infections
Interventions: GSK3888550A RSV Maternal vaccine formulation 1, GSK3888550A RSV Maternal vaccine formulation 2, GSK3888550A RSV Maternal vaccine formulation 3, Placebo (Normal Saline); Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 502 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Lenexa, Kansas • Rochester, New York

Conditions: Autosomal Dominant Polycystic Kidney Disease
Interventions: Tolvaptan MR, Tolvaptan IR; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 6
States / cities: Boston, Massachusetts • Minneapolis, Minnesota • Rochester, Minnesota + 3 more

Conditions: Endothelial Dysfunction, Aging
Interventions: Aronia full spectrum - half dose, Aronia full spectrum - full dose, Placebo; Dietary Supplement
Lead sponsor: Colorado State University; Other
Eligibility: 45 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Fort Collins, Colorado

Search by objective public record fields.

Safety and Maintenance of Effect of Ziprasidone Plus a Mood Stabilizer in Bipolar I Disorder (Manic or Mixed)

Study to Evaluate NRCT-101SR in Adult Attention Deficit Hyperactivity Disorder (ADHD)

Study to Evaluate Equivalence of Estradiol Vaginal Cream 0.01% to Estrace® Cream 0.01% in Atrophic Vaginitis

A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children.

A Randomized, Double Blind Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986166 in Healthy Subjects

Efficacy and Safety Study of JNJ-32729463 Compared With Moxifloxacin for the Treatment of Subjects Requiring Hospitalization for Community-Acquired Bacterial Pneumonia

Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease

Safety and Efficacy of USB002 for Respiratory Distress Due to COVID-19

Acute Otitis Media (AOM) Therapy Trial in Young Children

Study Evaluating the Efficacy, Safety, and Tolerability of ASY202 (Dihydroergotamine Mesylate [DHE] Inhalation Powder Delivered Via a Multidose Dry Powder Inhaler) for the Acute Treatment of Migraine in Adult Patients

Phase 1 Study on Bioavailability, Food Effect, and Drug-Drug Interaction of ALG-097558 Tablets in Healthy Volunteers

BXQ-350 Pharmacokinetic/Pharmacodynamic Study in Cancer Patients

Daily Topical Rapamycin for Vitiligo

A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine GSK3206641A Administered in Adults 18 to 64 Years of Age and 65 Years of Age and Older

Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine With Various Formulations in Adults >= 50 Years

MitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction

A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy

A Two-part Study to Compare a Tablet and Capsule Formulation of GSK2838232 With and Without Food, and to Assess the Safety and Drug Levels of Repeated Once-daily Doses of GSK2838232 Without Ritonavir

Tandem OnabotulinumtoxinA Galcanezumab Emerging Therapeutic Headache Elimination Research Study

(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis

A Trial of Levodopa in Angelman Syndrome

A Study to Evaluate Different Dose Levels of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3888550A), Based on the Vaccine Safety and the Antibodies (Body Defences) Produced Following Vaccine Administration, When Given to Healthy Non-pregnant Women

Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD

Effects of Aronia Berries on Vascular Endothelial Function and the Gut Microbiota in Middle-Aged/Older Adults